Agilent beats Q3 estimates and raises FY26 outlook, tariff refund masks part of upside

The quarter cleared the market’s bar by a meaningful margin. Non-GAAP EPS was $1.62 versus published consensus of about $1.49, while revenue reached $1.878 billion versus roughly $1.84 billion expected. The $0.06-per-share tariff-refund benefit helped, but stripping it out still leaves approximately $1.56 of adjusted EPS — a clear beat rather than a one-off accounting win.

The upside was broad enough to support another outlook increase. Revenue grew across all three segments, led by Life Sciences and Diagnostics at 11% reported growth, while CrossLab grew 6% and Applied Markets 7%. Companywide non-GAAP operating margin expanded to 28.3% from 25.1%, showing that the result was not solely revenue-driven.

Management raised the full-year framework again, making the guidance signal more important than the quarter alone. FY26 revenue is now expected at $7.49 billion to $7.51 billion, with the midpoint 65 basis points higher on the reported growth outlook; non-GAAP EPS guidance increased by $0.15 at the midpoint.

The main qualification is that part of the EPS and margin lift came from tariff refunds, but it does not erase the beat. The refund contributed $17 million to net income and six cents to EPS, while the company explicitly excluded future tariff-refund benefits from fourth-quarter guidance. Even after that adjustment, the quarter exceeded consensus and the underlying core revenue growth rate accelerated to 7.3%, so the net read is a genuine beat with a raised outlook, not merely favorable framing. 〔0〕